mortality factor 4 like 2Genealiases: MORFL2 · MRGX
Q-omics provides the consensus-scored MORF4L2 profile across patient tissues and cancer cell-line models. MORF4L2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MORF4L2 is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, MORF4L2 protein abundance shows 22,974 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, and LSCC as cancer lineages where MORF4L2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MORF4L2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MORF4L2 survival associations across molecular data types. MORF4L2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MORF4L2 RNA expression–survival associations across cancer types. High MORF4L2 expression shows unfavorable associations in HNSC, KIRP, UVM, MESO and LUSC, but favorable associations in KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MORF4L2 RNA expression.
This table summarizes MORF4L2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MORF4L2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MORF4L2 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, BLCA, LIHC and COAD. The HNSC box plot shows higher MORF4L2 RNA expression in tumor versus normal tissue (log2 FC = +1.171, t-test p < 0.001).
This table shows molecular features associated with MORF4L2 in patient tissues and cancer cell lines. In patient samples, MORF4L2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MORF4L2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and UPPER_AERODIGESTIVE_TRACT.
